Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk

Robert S. White, Richard B. Lipton, Charles B. Hall, Joshua R. Steinerman

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To explore the association of nonmelanoma skin cancer (NMSC) and Alzheimer disease (AD) in the Einstein Aging Study, an epidemiologic study of aging in New York City. Methods: Community-residing volunteers aged 70 years or older were assessed annually, followed by multidisciplinary diagnostic consensus. Cancer status and type was obtained by self-report. Cox proportional hazards models were used to test associations between NMSC and subsequent risk of developing a neurocognitive disorder. To deduce a biologically specific association between AD and NMSC, we considered 3 nested outcomes groups: only AD (probable or possible AD as the sole diagnosis), any AD (probable AD or possible AD, as well as mixed AD/vascular dementia), and all-cause dementia. Results: We followed 1,102 adults with a mean age of 79 years at enrollment. Prevalent NMSC was associated with reduced risk of only AD (hazard ratio = 0.21;95% confidence interval = 0.051-0.87; p = 0.031) among subjects after adjustment for demographics, hypertension, diabetes, and coronary heart disease. APOE s4 genotypes were available in 769 individuals. The association was similar in magnitude, but nonsignificant, when the number of APOE s4 alleles was included in the model. No significant association was found between NMSC and subsequent development of any AD or all-cause dementia. Conclusions: This population-based longitudinal study shows that individuals older than 70 years with NMSC have a significantly reduced risk of developing AD compared with individuals without NMSC. We deduce Alzheimer-specific neuroprotection, because the effect is attenuated or eliminated when considering less-specific diagnoses such as AD with another diagnosis (any AD) or all-cause dementia.

Original languageEnglish (US)
Pages (from-to)1966-1972
Number of pages7
JournalNeurology
Volume80
Issue number21
DOIs
StatePublished - May 21 2013

Fingerprint

Skin Neoplasms
Alzheimer Disease
Dementia
Alzheimer's Disease
Cancer
Vascular Dementia
Proportional Hazards Models
Skin Diseases
Self Report
Coronary Disease
Longitudinal Studies
Epidemiologic Studies
Volunteers
Consensus
Alleles
Genotype
Demography
Confidence Intervals

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. / White, Robert S.; Lipton, Richard B.; Hall, Charles B.; Steinerman, Joshua R.

In: Neurology, Vol. 80, No. 21, 21.05.2013, p. 1966-1972.

Research output: Contribution to journalArticle

White, Robert S. ; Lipton, Richard B. ; Hall, Charles B. ; Steinerman, Joshua R. / Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. In: Neurology. 2013 ; Vol. 80, No. 21. pp. 1966-1972.
@article{2edd01a23e8d4ce0914657c5cbc9369c,
title = "Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk",
abstract = "Objective: To explore the association of nonmelanoma skin cancer (NMSC) and Alzheimer disease (AD) in the Einstein Aging Study, an epidemiologic study of aging in New York City. Methods: Community-residing volunteers aged 70 years or older were assessed annually, followed by multidisciplinary diagnostic consensus. Cancer status and type was obtained by self-report. Cox proportional hazards models were used to test associations between NMSC and subsequent risk of developing a neurocognitive disorder. To deduce a biologically specific association between AD and NMSC, we considered 3 nested outcomes groups: only AD (probable or possible AD as the sole diagnosis), any AD (probable AD or possible AD, as well as mixed AD/vascular dementia), and all-cause dementia. Results: We followed 1,102 adults with a mean age of 79 years at enrollment. Prevalent NMSC was associated with reduced risk of only AD (hazard ratio = 0.21;95{\%} confidence interval = 0.051-0.87; p = 0.031) among subjects after adjustment for demographics, hypertension, diabetes, and coronary heart disease. APOE s4 genotypes were available in 769 individuals. The association was similar in magnitude, but nonsignificant, when the number of APOE s4 alleles was included in the model. No significant association was found between NMSC and subsequent development of any AD or all-cause dementia. Conclusions: This population-based longitudinal study shows that individuals older than 70 years with NMSC have a significantly reduced risk of developing AD compared with individuals without NMSC. We deduce Alzheimer-specific neuroprotection, because the effect is attenuated or eliminated when considering less-specific diagnoses such as AD with another diagnosis (any AD) or all-cause dementia.",
author = "White, {Robert S.} and Lipton, {Richard B.} and Hall, {Charles B.} and Steinerman, {Joshua R.}",
year = "2013",
month = "5",
day = "21",
doi = "10.1212/WNL.0b013e3182941990",
language = "English (US)",
volume = "80",
pages = "1966--1972",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

TY - JOUR

T1 - Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk

AU - White, Robert S.

AU - Lipton, Richard B.

AU - Hall, Charles B.

AU - Steinerman, Joshua R.

PY - 2013/5/21

Y1 - 2013/5/21

N2 - Objective: To explore the association of nonmelanoma skin cancer (NMSC) and Alzheimer disease (AD) in the Einstein Aging Study, an epidemiologic study of aging in New York City. Methods: Community-residing volunteers aged 70 years or older were assessed annually, followed by multidisciplinary diagnostic consensus. Cancer status and type was obtained by self-report. Cox proportional hazards models were used to test associations between NMSC and subsequent risk of developing a neurocognitive disorder. To deduce a biologically specific association between AD and NMSC, we considered 3 nested outcomes groups: only AD (probable or possible AD as the sole diagnosis), any AD (probable AD or possible AD, as well as mixed AD/vascular dementia), and all-cause dementia. Results: We followed 1,102 adults with a mean age of 79 years at enrollment. Prevalent NMSC was associated with reduced risk of only AD (hazard ratio = 0.21;95% confidence interval = 0.051-0.87; p = 0.031) among subjects after adjustment for demographics, hypertension, diabetes, and coronary heart disease. APOE s4 genotypes were available in 769 individuals. The association was similar in magnitude, but nonsignificant, when the number of APOE s4 alleles was included in the model. No significant association was found between NMSC and subsequent development of any AD or all-cause dementia. Conclusions: This population-based longitudinal study shows that individuals older than 70 years with NMSC have a significantly reduced risk of developing AD compared with individuals without NMSC. We deduce Alzheimer-specific neuroprotection, because the effect is attenuated or eliminated when considering less-specific diagnoses such as AD with another diagnosis (any AD) or all-cause dementia.

AB - Objective: To explore the association of nonmelanoma skin cancer (NMSC) and Alzheimer disease (AD) in the Einstein Aging Study, an epidemiologic study of aging in New York City. Methods: Community-residing volunteers aged 70 years or older were assessed annually, followed by multidisciplinary diagnostic consensus. Cancer status and type was obtained by self-report. Cox proportional hazards models were used to test associations between NMSC and subsequent risk of developing a neurocognitive disorder. To deduce a biologically specific association between AD and NMSC, we considered 3 nested outcomes groups: only AD (probable or possible AD as the sole diagnosis), any AD (probable AD or possible AD, as well as mixed AD/vascular dementia), and all-cause dementia. Results: We followed 1,102 adults with a mean age of 79 years at enrollment. Prevalent NMSC was associated with reduced risk of only AD (hazard ratio = 0.21;95% confidence interval = 0.051-0.87; p = 0.031) among subjects after adjustment for demographics, hypertension, diabetes, and coronary heart disease. APOE s4 genotypes were available in 769 individuals. The association was similar in magnitude, but nonsignificant, when the number of APOE s4 alleles was included in the model. No significant association was found between NMSC and subsequent development of any AD or all-cause dementia. Conclusions: This population-based longitudinal study shows that individuals older than 70 years with NMSC have a significantly reduced risk of developing AD compared with individuals without NMSC. We deduce Alzheimer-specific neuroprotection, because the effect is attenuated or eliminated when considering less-specific diagnoses such as AD with another diagnosis (any AD) or all-cause dementia.

UR - http://www.scopus.com/inward/record.url?scp=84879081909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879081909&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3182941990

DO - 10.1212/WNL.0b013e3182941990

M3 - Article

VL - 80

SP - 1966

EP - 1972

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 21

ER -